Climb Bio, Inc. (CLYM)
14.25
-0.70
(-4.68%)
USD |
NASDAQ |
Sep 11, 16:00
14.25
0.00 (0.00%)
After-Hours: 20:00
Climb Bio Debt to Equity Ratio : 0.0055 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0055 |
| March 31, 2026 | 0.0032 |
| December 31, 2025 | 0.0034 |
| September 30, 2025 | 0.0033 |
| June 30, 2025 | 0.0034 |
| March 31, 2025 | 0.0025 |
| December 31, 2024 | 0.0025 |
| September 30, 2024 | 0.0003 |
| June 30, 2024 | 0.0004 |
| March 31, 2024 | 0.0021 |
| December 31, 2023 | 0.0032 |
| Date | Value |
|---|---|
| September 30, 2023 | 0.0042 |
| June 30, 2023 | 0.0052 |
| March 31, 2023 | 0.0059 |
| December 31, 2022 | 0.0037 |
| September 30, 2022 | 0.0042 |
| June 30, 2022 | 0.0049 |
| March 31, 2022 | 0.0054 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Artiva Biotherapeutics, Inc. | 0.0283 |
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Oncolytics Biotech, Inc. | -0.0726 |
| Sangamo Therapeutics, Inc. | -1.020 |
| Sarepta Therapeutics, Inc. | 0.6845 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 246.29M |
| Total Liabilities (Quarterly) | 6.747M |
| Shareholders Equity (Quarterly) | 239.55M |
| Current Ratio | 31.45 |
| Net Debt Paydown Yield | -0.02% |